CLOs on the Move

Oyster Point Pharma

www.oysterpointrx.com

 
Based in Princeton, New Jersey, Oyster Point Pharma is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The company`s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the trigeminal parasympathetic pathway to activate the glands responsible for tear film production. Oyster Point is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate natural tear film production. The two lead product candidates, ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Raegan McClain
 Vice President and Chief Ethics, Compliance and Risk Management Officer Profile
Barry Rosenfeld
 Senior Director, Corporate Counsel Profile
Barry Rosenfeld
 Senior Vice President and General Counsel Profile
Jill Andersen
 General Counsel and Chief Compliance Officer Profile
Jill Andersen
 General Counsel, Corporate Secretary and Chief Compliance Officer Profile

Similar Companies

Service Drug Company

Service Drug Company is a Delta, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

biopharmservices

biopharmservices is a Acton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

fusionmed

fusionmed is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Mustang Bio

Mustang Bio, Inc., a subsidiary of Fortress Biotech, Inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient`s own immune system to eliminate cancer cells. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. Mustang has partnered with the City of Hope National Medical Center (“COH”) and Fred Hutchinson Cancer Research Center in the development of proprietary chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies across many cancers. Mustang`s lead programs are in Phase 1 clinical trials at COH: MB-101 for the treatment of brain cancer and MB-102 as a therapeutic agent in acute myeloid leukemia.

iTherX

iTherX is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.